Expertise Expertise Specialists in plastic and aesthetic surgery with membership of leading specialist associations Expertise Specialists in plastic and aesthetic surgery with membership of leading specialist associations Experience Experience Over 15 years of experience in plastic and aesthetic surgery, specializing in the latest methods such as VASER and Renuvion Experience Over 15 years of experience in plastic and aesthetic surgery, specializing in the latest methods such as VASER and Renuvion Quality Quality Gentle fast recovery methods with natural results, outpatient procedures Quality Gentle fast recovery methods with natural results, outpatient procedures Trust Trust Multilingual team of experts, treatment exclusively by specialists, personal support, excellent ratings Trust Multilingual team of experts, treatment exclusively by specialists, personal support, excellent ratings come as you are, leave as you wish.
This drug works by indirectly replenishing glutathione
Shingrix will replace the previously funded vaccine Zostavax (which was available for patients over 70 years old)
Antioxidants 11 , 1817 (2022)
AASLD: Hepatitis Debrief: The Liver Meeting 2018 - (11/19/18) HBV Therapies in Development - (11/15/17) Drugs in Development for Hepatitis B 2017 - Compounds in Development for Chronic Hepatitis B - Updated January 2019 AASLD: Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Patients with Chronic Hepatitis B - (02/13/19) AASLD: FINAL RESULTS OF A PHASE 1B 28-DAY STUDY OF ABI-H0731, A NOVEL CORE INHIBITOR, IN NON-CIRRHOTIC VIREMIC SUBJECTS WITH CHRONIC HBV - (02/13/19) AASLD: First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO-HBV - (02/13/19) AASLD: TLR7 agonist RO7020531 triggers immune activation after multiple doses in chronic hepatitis B patients - (02/13/19) AASLD: Limited sustained response and lack of HBsAg decline after stopping long-term nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results of the prospective, randomized, open-label phase IV STOP study - (02/13/19) AASLD: Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNin patientswithchronicHBV/HDV co-infection - (02/13/19) AASLD: PREDICTABILITY OF SERUM HBcrAg, HBsAg AND INTERFERON INDUCIBLE PROTEIN 10 (IP10) LEVELS IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS WHO DISCONTINUE ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY: RESULTS FROM THE PROSPECTIVE DARING-B STUDY - (01/02/19) AASLD: KINETICS OF SERUM HEPATITIS B CORE RELATED ANTIGEN (HBcrAg) IN NON-CIRRHOTIC HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) PATIENTS WHO DISCONTINUE EFFECTIVE LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) - (01/02/19) AASLD: Safety, Pharmacokinetics, and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients With Chronic Hepatitis B: a Randomized, Placebo-Controlled, Double-blind Phase 1b Study - (12/31/18) AASLD: No Resistance to Tenofovir Alafenamide Detected Through 144 Weeks of Treatment in Patients With Chronic Hepatitis B - (12/31/18) AASLD: 3-Year Efficacy and Safety of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in HBeAg-Negative and -Positive Patients With Chronic Hepatitis B - (12/31/18) AASLD: Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year After Switching to Tenofovir Alafenamide From Tenofovir Disoproxil Fumarate - (12/31/18) AASLD: Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort - (12/17/18) AASLD: Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV) - (12/17/18) AASLD: In Vitro Antiviral Activity and Mode of Action of JNJ-64530440, a Novel Potent Hepatitis B Virus Capsid Assembly Modulator in Clinical Development - (12/17/18) AASLD: ALT levels and risk of hepatocellular carcinoma in Caucasian chronic hepatitis B (CHB) patients under long-term therapy with entecavir or tenofovir disoproxil fumarate - (12/17/18) AASLD: Early adoption of tenofovir alafenamide (TAF) for Hepatitis B in US clinical practice
